ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.68), $0.02 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $960 thousand versus the consensus estimate of $4.36 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.